Fulcrum Therapeutics
FULC
101 hedge funds and large institutions have $197M invested in Fulcrum Therapeutics in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 25 closing their positions.
1,200% more call options, than puts
Call options by funds: $4.55M | Put options by funds: $350K
82% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 22
0.8% more ownership
Funds ownership: 97.13% → 97.93% (+0.8%)
6% less funds holding
Funds holding: 108 → 101 (-7)
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
79% less capital invested
Capital invested by funds: $918M → $197M (-$721M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.3M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$9.28M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$7.25M |
| 4 |
BlackRock
New York
|
+$4.16M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$16.4M |
| 2 |
CAC
Cowen and Company
New York
|
-$10.4M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$5.6M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.43M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$5.04M |
FULC Hedge Fund Activity: Q2 2022 in Review
101 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q2 2022, worth a combined $197M — down 79% from $918M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of FULC and 19 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 40 added.
The largest buyer was Point72 Asset Management, adding an estimated $16.3M. The largest seller was Adage Capital Partners, cutting an estimated $16.4M.
- 101 institutional investors held Fulcrum Therapeutics (FULC) as of Q2 2022, down from 108 in Q1 2022.
- Funds reported $197M of Fulcrum Therapeutics stock for Q2 2022, down 79% quarter-over-quarter.
- 19 funds opened new Fulcrum Therapeutics positions in Q2 2022 and 25 closed out, a net change of -6 holders.
- The largest Fulcrum Therapeutics buyer in Q2 2022 was Point72 Asset Management, an estimated $16.3M added.
- The largest Fulcrum Therapeutics seller in Q2 2022 was Adage Capital Partners, an estimated $16.4M sold.
Based on aggregated 13F filings for Q2 2022.